Skip to content

Study · Animal study (in vivo) · rat · 2012

10 results

Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats.

van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, Booij J

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology1 Sept 2011Cited by 20 (Europe PMC)

PMID21889317 (opens in a new tab)DOI10.1016/j.euroneuro.2011.07.015 (opens in a new tab)PepBankPUB-21889317
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In obese rats, tesofensine reduced caloric intake significantly more than vehicle.

    In plain wordsIn obese rats, tesofensine reduced caloric intake significantly more than vehicle.

    Peptide
    Tesofensine
    Outcome
    DecreaseCaloric intake
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.0 mg/kg · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Caloric intake and weight gain decreased significantly more in the tesofensine-treated rats compared to vehicle-treated rats, which confirms previous findings.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In obese rats, tesofensine reduced weight gain significantly more than vehicle.

    In plain wordsIn obese rats, tesofensine reduced weight gain significantly more than vehicle.

    Peptide
    Tesofensine
    Outcome
    DecreaseWeight gain
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.0 mg/kg · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Caloric intake and weight gain decreased significantly more in the tesofensine-treated rats compared to vehicle-treated rats, which confirms previous findings.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In obese rats, tesofensine reduced nucleus accumbens D2/D3 receptor availability compared with vehicle.

    In plain wordsIn obese rats, tesofensine reduced nucleus accumbens D2/D3 receptor availability compared with vehicle.

    Peptide
    Tesofensine
    Outcome
    DecreaseAccumbal D2/D3 receptor availability
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tesofensine-treated rats showed significantly lower D2/3R availability in nucleus accumbens and dorsal striatum than both vehicle-treated rats and vehicle-treated rats on restricted isocaloric diet.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In obese rats, tesofensine reduced nucleus accumbens D2/D3 receptor availability compared with vehicle plus a restricted isocaloric diet.

    In plain wordsIn obese rats, tesofensine reduced nucleus accumbens D2/D3 receptor availability compared with vehicle plus a restricted isocaloric diet.

    Peptide
    Tesofensine
    Outcome
    DecreaseAccumbal D2/D3 receptor availability
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Vehicle with restricted isocaloric diet
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tesofensine-treated rats showed significantly lower D2/3R availability in nucleus accumbens and dorsal striatum than both vehicle-treated rats and vehicle-treated rats on restricted isocaloric diet.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In obese rats, tesofensine reduced dorsal striatal D2/D3 receptor availability compared with vehicle.

    In plain wordsIn obese rats, tesofensine reduced dorsal striatal D2/D3 receptor availability compared with vehicle.

    Peptide
    Tesofensine
    Outcome
    DecreaseDorsal striatal D2/D3 receptor availability
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tesofensine-treated rats showed significantly lower D2/3R availability in nucleus accumbens and dorsal striatum than both vehicle-treated rats and vehicle-treated rats on restricted isocaloric diet.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In obese rats, tesofensine reduced dorsal striatal D2/D3 receptor availability compared with vehicle plus a restricted isocaloric diet.

    In plain wordsIn obese rats, tesofensine reduced dorsal striatal D2/D3 receptor availability compared with vehicle plus a restricted isocaloric diet.

    Peptide
    Tesofensine
    Outcome
    DecreaseDorsal striatal D2/D3 receptor availability
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Vehicle with restricted isocaloric diet
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tesofensine-treated rats showed significantly lower D2/3R availability in nucleus accumbens and dorsal striatum than both vehicle-treated rats and vehicle-treated rats on restricted isocaloric diet.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.

Studies that did not test the peptide alone4

In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tesofensine.

  1. 07AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Efficacy outcome

    In obese rats, caloric intake gradually increased again after tesofensine discontinuation.

    In plain wordsIn obese rats, caloric intake gradually increased again after tesofensine discontinuation.

    Peptide
    Tesofensine
    Outcome
    IncreaseCaloric intake after discontinuation
    Study

    ratn = 15

    Diet-induced obese rats
    Comparator
    During treatment
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    After treatment discontinuation, caloric intake and body weight gain gradually increased again.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  2. 08AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Efficacy outcome

    In obese rats, body weight gain gradually increased again after tesofensine discontinuation.

    In plain wordsIn obese rats, body weight gain gradually increased again after tesofensine discontinuation.

    Peptide
    Tesofensine
    Outcome
    IncreaseWeight gain after discontinuation
    Study

    ratn = 15

    Diet-induced obese rats
    Comparator
    During treatment
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    After treatment discontinuation, caloric intake and body weight gain gradually increased again.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  3. 09AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Mechanism

    In the rat tesofensine study, food intake did not correlate with D2/D3 receptor availability.

    In plain wordsIn rats, food intake did not correlate with D2/D3 receptor availability in the tesofensine study.

    Peptide
    Tesofensine
    Outcome
    No significant changeFood intake and receptor availability correlation
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    No correlations were observed between food intake or body weight and D2/3R availability.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  4. 10AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Mechanism

    In the rat tesofensine study, body weight did not correlate with D2/D3 receptor availability.

    In plain wordsIn rats, body weight did not correlate with D2/D3 receptor availability in the tesofensine study.

    Peptide
    Tesofensine
    Outcome
    No significant changeBody weight and receptor availability correlation
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    No correlations were observed between food intake or body weight and D2/3R availability.
    1 context sentence
    Summary · context
    Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg)+ a treatment-free period of 28 days.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.